World Health Organization Global tuberculosis report (2024) WHO, Geneva Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/data. Accessed June 2025

Houben RM, Dodd PJ (2016) The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 13(10):e1002152. https://doi.org/10.1371/journal.pmed.1002152

Article  PubMed  PubMed Central  Google Scholar 

Cohen AMV, Schön T, Wejse C (2019) The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 54(3):1900655. https://doi.org/10.1183/13993003

Article  PubMed  Google Scholar 

Khabibullina NF, Kutuzova DM, Burmistrova IA, Lyadova IV (2022) The biological and clinical aspects of a latent tuberculosis infection. Trop Med Infect Dis7(3):48. https://doi.org/10.3390/tropicalmed7030048

Article  PubMed  PubMed Central  Google Scholar 

Campbell JRWN, Menzies D (2020) Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ 368:m549. https://doi.org/10.1136/bmj.m5

Article  PubMed  PubMed Central  Google Scholar 

Goletti DDG, Matteelli A, Migliori GB (2022) The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int J Infect Dis124(1):S12–S19. https://doi.org/10.1016/j.ijid.2022.02.047

Article  CAS  PubMed  Google Scholar 

Kestler BTSdaP, PMC8934672 (2022) Latent tuberculosis testing through the ages: the search for a sleeping killer. Am J Physiol Lung Cell Mol Physiol 322(3):L412–L9. https://doi.org/10.1152/ajplung.00217.2021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pai MZA, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:77–84. https://doi.org/10.7326/0003-4819-149-3-200808050-00241

Article  Google Scholar 

Coussens AK, Zaidi SMA, Allwood BW, Dewan PK, Gray G, Kohli M et al (2024) Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise. Lancet Respir Med 12(6):484–498. https://doi.org/10.1016/S2213-2600(24)00028-6

Article  PubMed  PubMed Central  Google Scholar 

Ferebee SH, Palmer CE (1956) Prevention of experimental tuberculosis with isoniazid. Am Rev Tuberc 1/956 Jan;73(1):7(1):1–18 https://doi.org/10.1164/artpd.1956.73.1.1

Article  CAS  PubMed  Google Scholar 

Comstock GW, Ferebee SH, Hammes LM (1967) A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 95(6):935–943. https://doi.org/10.1164/arrd.1967.95.6.935

Article  CAS  PubMed  Google Scholar 

Diel R, Nienhaus A, Schaberg T (2005) Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 26(3):465–473. https://doi.org/10.1183/09031936.05.00047805

Article  CAS  PubMed  Google Scholar 

Nolan CM, Goldberg SV, Buskin SE (1999) Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 281(11):1014–1018. https://doi.org/10.1001/jama.281.11.1014

Article  CAS  PubMed  Google Scholar 

Kopanoff DE, Snider DE Jr, Caras GJ (1978) Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117(6):991–1001. https://doi.org/10.1164/arrd.1978.117.6.991

Article  CAS  PubMed  Google Scholar 

Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E et al (1993) A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 7(10):1345–1349. https://doi.org/10.1097/00002030-199310000-00007

Article  CAS  PubMed  Google Scholar 

Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. (1993) Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342(8866 ):268–72. https://doi.org/10.1016/0140-6736(93)91817-6

Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, Muñoz P (2009) Documento de consenso para el tratamiento de la tuberculosis en pacientes con trasplante de órgano sólido [Consensus document for the management of tuberculosis in solid organ transplant recipients]. Enferm Infecc Microbiol Clin 27(8):465–473 Spanish. https://doi.org/10.1016/j.eimc.2008.10.008

Article  PubMed  Google Scholar 

World Health Organization (2020) WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. World Health Organization. https://iris.who.int/handle/10665/331170. Accessed 19 July 2023

Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J et al (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845–855. https://doi.org/10.1038/nrmicro2236

González-Martín J, García-García JM, Anibarro L, Vidal R, Esteban J, Blanquer R et al (2010) Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis. Enferm Infecc Microbiol Clin 28(5):297.e1–20. https://doi.org/10.1016/j.eimc.2010.02.006

Article  PubMed  Google Scholar 

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM et al (2005) BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766–1772. https://doi.org/10.1002/art.21043

Article  CAS  PubMed  Google Scholar 

Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, Douglas P et al (2015) Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 45(4):928–52. https://doi.org/10.1183/09031936.00214014

Article  PubMed  PubMed Central  Google Scholar 

Haley CA (2017) Treatment of latent tuberculosis infection. Microbiol Spectr 5(2):10.1128/microbiolspec.tnmi7-0039-2016. https://doi.org/10.1128/microbiolspec.TNMI7-0039-2

Article  PubMed  PubMed Central  Google Scholar 

Prevention ECfD IGO (2024) Tuberculosis surveillance and monitoring in Europe 2024–2022 data. Copenhagen: WHO Regional Office for Europe and Stockholm. Licence: CC BY 3.0

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D et al (2015) Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46(6):1563–76. https://doi.org/10.1183/13993003.01245-2015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melnychuk L, Perlman-Arrow S, Lisboa Bastos M, Menzies D (2023) A systematic review and meta-analysis of tuberculous preventive therapy adverse events. Clin Infect Dis 77(2):287–294. https://doi.org/10.1093/cid/ciad246

Article  CAS  PubMed  Google Scholar 

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H et al (2018) Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 379(5):440–453. https://doi.org/10.1056/NEJMoa1714283

Article  CAS  PubMed  Google Scholar 

Huang HL, Lee MR, Cheng MH, Lu PL, Huang CK, Sheu CC et al (2021) Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection. Clin Infect Dis 73(5):e1064–e1071. https://doi.org/10.1093/cid/ciaa1741

Article  PubMed  PubMed Central  Google Scholar 

Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE (2023) Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysisLancet. Respir Med 11(9):782–790. https://doi.org/10.1016/S2213-2600(23)00096-6

Article  CAS  Google Scholar 

Sullivan K, Pease C, Zwerling A, Mallick R, Van Dyk D, Mulpuru S et al (2021) Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low-incidence country. BMC Public Health 21(1):964. https://doi.org/10.1186/s12889-021-10733-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ (2016) Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 16:204. https://doi.org/10.1186/s12879-016-1550-y

Article  PubMed  PubMed Central  Google Scholar